FLOW CYTOMETRY, CD 19

The Flow Cytometry CD19 Test is a specialized immunophenotyping assay used to identify and quantify CD19-positive B lymphocytes, an important group of white blood cells responsible for antibody production and immune defense. CD19 is one of the most reliable and widely used markers for identifying B cells throughout most stages of their development.

Flow cytometry technology enables rapid analysis of thousands of cells within a sample, providing detailed information about B-cell populations and their characteristics. CD19 is routinely included in comprehensive flow cytometry panels used for the diagnosis, classification, and monitoring of leukemia, lymphoma, immunodeficiency disorders, and other hematological conditions.

Because CD19 is expressed on the majority of normal and abnormal B lymphocytes, it serves as a key marker for detecting B-cell disorders and evaluating immune system function. The test may be performed on peripheral blood, bone marrow aspirates, lymph node specimens, or other appropriate clinical samples.

Benefits of the Test

• Identifies and quantifies B lymphocytes
• Assists in diagnosing B-cell leukemias and lymphomas
• Helps evaluate immune system function
• Supports investigation of immunodeficiency disorders
• Assists disease classification and monitoring
• Provides valuable immunophenotypic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD19 testing for:

• Suspected B-cell leukemia
• Suspected B-cell lymphoma
• Chronic Lymphocytic Leukemia (CLL)
• Acute Lymphoblastic Leukemia (ALL)
• Immunodeficiency evaluation
• Lymphocyte subset analysis
• Monitoring hematological malignancies
• Assessment of abnormal blood counts

The test helps identify abnormal B-cell populations and contributes to accurate disease diagnosis and classification.

Preparation Before Test

The test may require:

• Peripheral blood sample
• Bone marrow aspirate
• Lymph node specimen
• Body fluid specimen
• Other clinically appropriate samples

Preparation generally includes:

• No fasting is required
• Inform your physician about current treatments
• Follow laboratory instructions for specimen collection

The procedure involves routine sample collection followed by advanced flow cytometric analysis.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on the complexity of the immunophenotyping panel.

Who Should Take This Test?

• Patients with suspected leukemia or lymphoma
• Individuals with abnormal lymphocyte counts
• Patients with recurrent infections
• Individuals with suspected immunodeficiency disorders
• Patients undergoing lymphocyte subset analysis
• Individuals referred by hematologists, oncologists, or immunologists

Flow Cytometry CD19 testing is an essential component of modern hematology and immunology diagnostics.

Clinical Significance

CD19 expression is commonly associated with:

• Normal B Lymphocytes
• Chronic Lymphocytic Leukemia (CLL)
• B-cell Acute Lymphoblastic Leukemia (B-ALL)
• Non-Hodgkin Lymphoma
• B-cell Lymphoproliferative Disorders
• Immunodeficiency Disorders
• Monoclonal B-cell Populations

Abnormal CD19-positive cell populations may indicate B-cell malignancies or immune system abnormalities requiring further evaluation.

Important Note

CD19 is typically interpreted alongside other markers such as CD20, CD22, CD23, CD5, CD10, CD45, Kappa, and Lambda Light Chains. Accurate diagnosis requires comprehensive interpretation of all flow cytometry findings together with clinical and laboratory information.